Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma - Seite 3

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the potential for synergistic treatment effect with the Company’s novel, systemically delivered, MC1R-targeted alpha-particle radiotherapy, [²¹²Pb]VMT01, in combination with nivolumab, a well-studied immunotherapy; the Company’s ability to continue expanding the clinical development of the Company’s radiotherapy with standard of care immunotherapy to bring novel solutions to patients suffering from in MC1R-Positive metastatic melanoma; the Company’s belief that the combination of [²¹²Pb]VMT01 with immune checkpoint inhibitors in a resistant preclinical melanoma model will continue demonstrating potential to generate a number of complete responses, significantly arresting tumor growth and extending survival; the Company’s ability to develop VMT01 for the treatment and diagnosis of MC1R-positive metastatic melanoma; the ability for VMT01 to be labeled with ²¹²Pb to deliver alpha-particle radiation directly to tumor cells, or ²⁰³Pb to enable patient selection, diagnostic imaging and dosimetry via SPECT imaging; the Company’s ability to develop successful proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting peptides provide the opportunity to personalize treatment and optimize patient outcomes; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments; the Company's clinical development plans and the expected timing thereof; the potential functionality, capabilities, and benefits of the Company's product candidates and the potential application of these product candidates for other disease indications; and the Company's expectations, beliefs, intentions, and strategies regarding the future; and other statements that are not historical fact.